Martin C Tammemägi1, Christine D Berg2, Thomas L Riley2, Christopher R Cunningham2, Kathryn L Taylor2. 1. Affiliations of authors: Department of Health Sciences, Brock University, St. Catharines, ON, Canada (MCT); Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD (CDB); Information Management Services, Rockville, MD (TLR, CRC); Department of Oncology, Lombardi Comprehensive Cancer Center, Cancer Control Program, Georgetown University, Washington, DC (KLT). martin.tammemagi@brocku.ca. 2. Affiliations of authors: Department of Health Sciences, Brock University, St. Catharines, ON, Canada (MCT); Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD (CDB); Information Management Services, Rockville, MD (TLR, CRC); Department of Oncology, Lombardi Comprehensive Cancer Center, Cancer Control Program, Georgetown University, Washington, DC (KLT).
Abstract
BACKGROUND: Lung cancer screening programs may provide opportunities to reduce smoking rates among participants. This study evaluates the impact of lung cancer screening results on smoking cessation. METHODS: Data from Lung Screening Study participants in the National Lung Screening Trial (NLST; 2002-2009) were used to prepare multivariable longitudinal regression models predicting annual smoking cessationin those who were current smokers at study entry (n = 15489, excluding those developing lung cancer in follow-up). The associations of lung cancer screening results on smoking cessation over the trial period were analyzed. All hypothesis testing used two sided P values. RESULTS: In adjusted analyses, smoking cessation was strongly associated with the amount of abnormality observed in the previous year's screening (P < .0001). Compared with those with a normal screen, individuals were less likely to be smokers if their previous year's screen had a major abnormality that was not suspicious for lung cancer (odds ratio [OR] = 0.811; 95% confidence interval [CI] = 0.722 to 0.912; P < .001), was suspicious for lung cancer but stable from previous screens (OR = 0.785; 95% CI = 0.706 to 0.872; P < .001), or was suspicious for lung cancer and was new or changed from the previous screen (OR = 0.663; 95% CI = 0.607 to 0.724; P < .001). Differences in smoking prevalence were present up to 5 years after the last screen. CONCLUSIONS:Smoking cessation is statistically significantly associated with screen-detected abnormality. Integration of effective smoking cessation programs within screening programs should lead to further reduction in smoking-related morbidity and mortality.
RCT Entities:
BACKGROUND:Lung cancer screening programs may provide opportunities to reduce smoking rates among participants. This study evaluates the impact of lung cancer screening results on smoking cessation. METHODS: Data from Lung Screening Study participants in the National Lung Screening Trial (NLST; 2002-2009) were used to prepare multivariable longitudinal regression models predicting annual smoking cessation in those who were current smokers at study entry (n = 15489, excluding those developing lung cancer in follow-up). The associations of lung cancer screening results on smoking cessation over the trial period were analyzed. All hypothesis testing used two sided P values. RESULTS: In adjusted analyses, smoking cessation was strongly associated with the amount of abnormality observed in the previous year's screening (P < .0001). Compared with those with a normal screen, individuals were less likely to be smokers if their previous year's screen had a major abnormality that was not suspicious for lung cancer (odds ratio [OR] = 0.811; 95% confidence interval [CI] = 0.722 to 0.912; P < .001), was suspicious for lung cancer but stable from previous screens (OR = 0.785; 95% CI = 0.706 to 0.872; P < .001), or was suspicious for lung cancer and was new or changed from the previous screen (OR = 0.663; 95% CI = 0.607 to 0.724; P < .001). Differences in smoking prevalence were present up to 5 years after the last screen. CONCLUSIONS: Smoking cessation is statistically significantly associated with screen-detected abnormality. Integration of effective smoking cessation programs within screening programs should lead to further reduction in smoking-related morbidity and mortality.
Authors: Lisa Sanderson Cox; Matthew M Clark; James R Jett; Christi A Patten; Darrell R Schroeder; Liza M Nirelli; Stephen J Swensen; Richard D Hurt Journal: Cancer Date: 2003-12-01 Impact factor: 6.860
Authors: Michael T Jaklitsch; Francine L Jacobson; John H M Austin; John K Field; James R Jett; Shaf Keshavjee; Heber MacMahon; James L Mulshine; Reginald F Munden; Ravi Salgia; Gary M Strauss; Scott J Swanson; William D Travis; David J Sugarbaker Journal: J Thorac Cardiovasc Surg Date: 2012-07 Impact factor: 5.209
Authors: C M van der Aalst; R J van Klaveren; K A M van den Bergh; M C Willemsen; H J de Koning Journal: Eur Respir J Date: 2010-12-09 Impact factor: 16.671
Authors: Cynthia O Townsend; Matthew M Clark; James R Jett; Christi A Patten; Darrell R Schroeder; Liza M Nirelli; Stephen J Swensen; Richard D Hurt Journal: Cancer Date: 2005-05-15 Impact factor: 6.860
Authors: Christy M Anderson; Rowena Yip; Claudia I Henschke; David F Yankelevitz; Jamie S Ostroff; David M Burns Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-12 Impact factor: 4.254
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; Jonathan D Clapp; Kathy L Clingan; Ilana F Gareen; David A Lynch; Pamela M Marcus; Paul F Pinsky Journal: J Natl Cancer Inst Date: 2010-11-22 Impact factor: 13.506
Authors: Alana M Rojewski; Nichole T Tanner; Lin Dai; James G Ravenel; Mulugeta Gebregziabher; Gerard A Silvestri; Benjamin A Toll Journal: Chest Date: 2018-05-21 Impact factor: 9.410
Authors: Pianpian Cao; Jihyoun Jeon; David T Levy; Jinani C Jayasekera; Christopher J Cadham; Jeanne S Mandelblatt; Kathryn L Taylor; Rafael Meza Journal: J Thorac Oncol Date: 2020-03-08 Impact factor: 15.609
Authors: Melissa A Clark; Jeremy J Gorelick; JoRean D Sicks; Elyse R Park; Amanda L Graham; David B Abrams; Ilana F Gareen Journal: Nicotine Tob Res Date: 2015-03-06 Impact factor: 4.244
Authors: Lauren R Meltzer; Marina Unrod; Vani N Simmons; Karen O Brandon; Bárbara Piñeiro; Amanda M Palmer; Thomas H Brandon Journal: Lung Cancer Date: 2019-02-18 Impact factor: 5.705
Authors: Marc R Freiman; Jack A Clark; Christopher G Slatore; Michael K Gould; Steven Woloshin; Lisa M Schwartz; Renda Soylemez Wiener Journal: J Thorac Oncol Date: 2016-03-07 Impact factor: 15.609
Authors: Andrea K Borondy Kitts; Andrea B McKee; Shawn M Regis; Christoph Wald; Sebastian Flacke; Brady J McKee Journal: J Thorac Dis Date: 2016-07 Impact factor: 2.895